Booster doses are recommended for adults because immunity after the primary vaccination series declines over time and because viral evolution can reduce the protection conferred by earlier doses. Evidence from clinical and population studies shows that an additional vaccine dose restores antibody levels and strengthens protection against severe disease, hospitalization, and death. A study by Yinon M. Bar-On at Weizmann Institute of Science demonstrated that a third dose of an mRNA vaccine significantly reduced rates of confirmed infection and serious illness compared with two doses, supporting the role of boosters in sustaining population-level protection.
Why boosters work
The immune response to vaccination involves both antibodies and memory cells. After the initial series, antibody levels typically wane, which can leave people more susceptible to infection months later, especially when a variant with immune-evading changes is circulating. Boosters increase circulating antibodies and elicit a broader memory response that improves the immune system’s ability to recognize and neutralize variants. Guidance from Soumya Swaminathan at World Health Organization explains that booster doses can be particularly useful when transmission is high or when vaccine-induced protection against infection has decreased, while continuing to prioritize primary immunization where coverage remains low.
Who benefits most
Booster recommendations target groups at higher risk of severe outcomes or waning immunity. Older adults, people with certain chronic conditions, and residents of long-term care facilities show greater declines in protection and greater benefit from additional doses. Public health agencies such as the Centers for Disease Control and Prevention with input from Amanda Cohn at CDC emphasize prioritizing these groups while also recognizing that adults across age groups may receive boosters to reduce symptomatic infection and interrupt transmission chains in communities with active spread.
Causes for recommending boosters therefore combine immunological mechanisms and epidemiological realities. When a variant reduces vaccine effectiveness moderately, or when antibody titers fall, the population experiences more breakthrough infections. Consequences of not boosting include increased rates of symptomatic disease, greater strain on healthcare systems, and elevated risk for vulnerable individuals. At the same time, widespread booster programs interact with global equity considerations: vaccinating low-risk adults in high-income countries while many people in low-income countries remain unvaccinated raises ethical and epidemiological concerns about variant emergence and long-term control, an issue highlighted by international public health experts.
Safety monitoring remains central to booster policies. Regulatory bodies and surveillance systems continue to evaluate adverse events after additional doses; overall safety profiles for boosters have been consistent with those seen after primary series doses, with most reactions being mild or transient and serious events remaining rare. Continued monitoring and transparent reporting are essential to maintain public trust.
In practical terms, boosters are a tool to maintain vaccine effectiveness in the face of waning immunity and viral change, targeted to reduce severe disease and preserve health system capacity while balancing global vaccine access and public confidence in immunization programs.